Clinical Trial

Italian Real-World Study of Epcoritamab in Relapsed or Refractory DLBCL

Name: Italian Real-World Study of Epcoritamab in Relapsed or Refractory DLBCL — clinical trial record (NCT07393204)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: EPKEY_HSR

Active, Not Recruiting

View on ClinicalTrials.gov →

Summary

This study describes the effectiveness of epcoritamab outside the clinical trial setting in pts with DLBCL relapsed or refractory after 2 or more previous lines of therapy

Trial Details

NCT Number	NCT07393204
Lead Sponsor	Andrés José Maria Ferreri
Conditions	Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-Cell Lymphoma
Enrollment	150 participants
Start Date	2025-12-10
Primary Completion	2026-12-10 (estimated)
Study Completion	2026-12-10 (estimated)
Updated on ClinicalTrials.gov	2026-02-06